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Type 1 diabetes mellitus may be associated with many autoimmune diseases with the common autoimmune
pathogenesis. We describe the case of a girl suffering from Type 1 diabetes mellitus and autoimmune Hashimoto's
thyroiditis since the childhood and, due to the onset of Juvenile Idiopathic Arthritis during adolescence, for three
years practiced therapy with an anti-TNF drug, etanercept . Currently her inflammatory markers are normal, arthritis
is inactive and diabetes is well controlled. During the treatment with anti-TNF drug we observed a significative
reduction of insulin dose, probably due to an increased tissue sensitivity secondary to the suppression of the
activity of TNF-alpha. Several clinical trials that have evaluated the effect of immunomodulatory agents in diabetic
patients, especially in those with recent onset of disease, were already performed but further studies of longer
duration on a larger population are needed to assess the role of biologic drugs and immunotherapy in this group
of patients.
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The coexistence of Juvenile Idiopathic Arthritis (JIA) with
Type 1 Diabetes Mellitus (T1DM) and Autoimmune
Hashimoto's Thyroiditis (AHT) may be considered rare
and it suggests a common genetic susceptibility [1,2]. The
HLA, CTLA4 and PTPN22 genes, which regulate the
activation of T-lymphocytes, have been associated with
specific organ autoimmune diseases and some of their
variants increase the risk of onset of these three diseases
[1,3]. We describe the case of a female patient suffering
since the childhood from T1DM and AHT and in therapy
with insulin and L-tiroxine, who developed JIA during
adolescence unresponsive to conventional therapy with
Non Steroid Anti Inflammatory Drugs (NSAIDs) and* Correspondence: alma.olivieri@unina2.it; dario.iafusco@unina2.it;
antonio.mellos@gmail.com
Department of the Woman, of the Child and of the General and Specialistic
Surgery, Second University of Naples (SUN), 2, via Luigi De Crecchio, Naples
80138, Italy
© 2013 Olivieri et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orMethotrexate (MTX) for which we started anti-TNF ther-
apy. In our patient after three weeks from the introduction
of etanercept, arthritis appeared in remission, without
disrupting her metabolism. Upon treatment with
etanercept, the daily insulin requirement was reduced,
probably due to an increased tissue sensitivity secondary
to the suppression of activity of TNF-alpha. Recently, a
small randomized pilot study has reported that this medi-
cation in addition to being safe and effective, would be
able in patients with T1DM of recent onset to prolong en-
dogenous insulin production thus suggesting the preserva-
tion of beta cell pancreatic function [4]. Several clinical
trials that have evaluated the effect of immunomodulatory
agents in diabetic patients, especially in those with recent
onset of disease, were already performed [5,6], but further
studies with a longer follow-up are needed to assess the
effectiveness and safety of immunotherapy in this group
of patients [5-7].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Etanercept led to a marked improvement in arthritis.
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The patient was in follow up in the Pediatric Diabetological
Center of our Department because developed type 1 dia-
betes at the age of 1 year and 5 months with the signs of
ketoacidosis preceded by polyuria, polydipsia, weight loss
and progressive weakness. Blood tests and laboratory re-
vealed on that occasion: pH 7.16, pCO2 35.4 mmHg, O2
saturation 66%, base excess - 14.8, bicarbonate 12.5 mEq/L,
glucose 587 mg/dl, HbA1c 11.4% (101 mmol/mol), serum
C-peptide 0.2 ng/ml (n.v. 0.6 -3.7) weakly positive ICA,
GADA 0.1 AU/ml (n.v. <3), IA-2 autoantibodies 33 AU/ml
(n.v. <1). The family history revealed that a maternal uncle
was suffering from diabetes mellitus since the age of 31
years old, treated initially with oral hypoglycemic drugs and
later with insulin. AHT was diagnosed at the age of 6
years and 9 months because the presence of autoanti-
bodies (anti-TgAbs 181,80 IU/ml and anti-TPOAbs
578.90 IU/ml) and because of the findings of the ultrasound
(US) and Doppler-US that showed respectively a hetero-
geneous echogenicity of the thyroid with multinodular
hypoechoic areas and a widespread hypervascularization. It
was necessary to introduce replacement therapy with L-
thyroxine 9 months later for the onset of hypothyroidism
(fT3 4.18 pg/ml, fT4 6.11 pg/ml; TSH 64.41 μIU/mL). At
the age of 11 years and 2 months old she was referred to
the Pediatric Rheumatological Center of our Department
for persistence, from approximately 6 months, of diffuse
arthralgia, morning stiffness lasting about an hour and
lameness. The insulin and thyroid replacement therapy had
been adequate up to that moment: in fact, her reference
percentiles for height (145 cm), weight (39.5 kg) and BMI
(18,8 ) were all included between the 25th and the 50th per-
centile [8] and the path of her growth curve had always
continued along this channel, without showing deflections
despite the medical history revealed that the patient suf-
fered from the joint symptoms since at least 6 months and
her metabolic state was very altered (HbA1c 10.4%; insulin
dose of 1.2 Units/Kg/day). Pubertal development was ap-
propriate to sex and age (P2B2) [9]. Physical examination
showed the presence of all the signs of arthritis of the el-
bows, wrists, hips, knees, left ankle, metacarpophalangeal
joints of the third and fifth finger of the left hand and
first and third finger of the right hand. Laboratory tests
found inflammatory anemia (hemoglobin 8.1 g/dl, ESR
125 mm/hour, CRP 25.8 mg/dl, fibrinogen 682 mg/dl,
serum iron 8 mcg/dl, ferritin 210 ng/ml) and bone
marrow aspirate excluded malignancies. The serological
tests for celiac and connective tissue disease (ENA) were
negative, but positive for rheumatoid factor (52 umol/L)
and for ANA (1:160); the eye examination excluded the
presence of concomitant iridocyclitis. Considering 2
further test for rheumatoid factor (RF) resulted positive
(28 umol/L, 33 umol/L; n.v. 0-20) at 3 months apart
during the first 6 months of disease, the diagnosis of RFpositive polyarthritis was made according with Inter-
national League of Associations for Rheumatology (ILAR)
classification criteria [10] and treatment with anti-
inflammatory drugs (Naproxen, 15 mg/kg/day) and MTX
at a dose of 15 mg/m2/week was assigned according to
2011 American College of Rheumatology (ACR) recco-
mandation [11]. After about a year of relatively good con-
trol of the arthritis, the patient had a progressive clinical
deterioration: the physical examination showed limitation
of flexion and extension of both wrists, elbows and the left
ankle which was also swollen. In view of this clinical pic-
ture and the persistence of inflammatory anemia (9.8 g/dl,
ESR 50 mm/hour, CRP 13.6 mg/dl) we decided to start
anti-TNF therapy (etanercept 0.4 mg/kg, subcutaneously,
twice in a week). We have decided not to suspend MTX,
the effectiveness of which is sustained by good-quality
studies [12], because the patient had always shown to
tolerate it well in combination with conventional ther-
apy based on NSAIDs although over time this treatment
proved insufficient to control arthritis, and to associate
it with the etanercept to enhance their mutual anti-
inflammatory and immunomodulatory activities [13].
The functional limitation of the affected joints was pro-
gressively reduced and the current examination show
only a slight functional limitation of both wrists in the
absence of further clinical and biochemical signs of
acute inflammation (ESR 13 mm/hour; CRP 0.1 mg/dl)
(Figure 1). Also the metabolic control of diabetes im-
proved and the HbA1c after three months from the
starting of biological therapy was 8.7% (71 mmol/mol)
and after 6 months was 8.3% (67 mmol/mol) while the
insulin dose decreased respectively to 1.0 and 0.8 units/
Kg/day (Figure 2). The patient continues to get the
beneficial effects of etanercept treatment and at the mo-
ment both the daily requirement of exogenous insulin
(0.8 U/kg/day), and the HbA1c (7.8%, 61 mmol/mol) are
significantly reduced compared to those found at the
diagnosis of arthritis. The current blood levels of fasting
C-peptide remains unchanged compared to those found
Figure 2 Changes over time in insulin dose and HbA1c.
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requirement of L-thyroxine is stable (1.7 mg/kg/ day) and
the arthritis is under control thanks to etanercept. Until
now, laboratory tests performed during follow-up for ce-
liac disease (ATA-IgA 2.5 U/ml; anti-gliadin peptides IgG
3.1 U/ml, anti-gliadin peptides IgA 1 U/ml), Addison's
disease (cortisol 7.3 mcg /dl, ACTH 16.9 pg/ml) were nor-
mal, as well as the current thyroid profile (fT3 3.2 pg/ml,
fT4 12.2 pg/ml; TSH 0,305 μUI /mL). From the clinical
onset of joint symptoms to date, the patient has grown
regularly along its growth channel (25th - 50th percentile)
and pubertal development is continued normally. Cur-
rently, she shows no signs of nephropathy or neuropathy,
does not suffer from high blood pressure and eye examin-
ation has ruled out so far the presence of diabetic retinop-
athy or iridocyclitis.
Discussion
Few cases have been reported about the association of
autoimmune diseases such as T1DM, HT, and JIA. Most
of these patients are predominantly female, diabetes
mellitus appeared first, followed by thyroiditis and, finally,
by arthritis. This may be due to the fact that some genes
involved in the pathogenesis and/or in susceptibility of
these three lymphocyte T autoimmune diseases have a
gender-dependent penetrance [1]. To date, insulin re-
placement therapy remains the mainstay of treatment of
patients with T1DM. Over the past 30 years, the introduc-
tion of multiple insulin formulations, each of which has a
different duration of action, has enriched the therapeuticarmamentarium for the management of diabetes. The
continuous development of improved insulin pumps and
glucose monitoring systems more efficient will further im-
prove glycemic control in these patients [6]. T1DM is a
chronic and predictable autoimmune disease with identifi-
able progressive stages for which there could be the
possibility of preventing progression to clinical symptoms
[14,15]. Currently, several studies are evaluating the role
of immunomodulatory agents and biological drugs for the
prevention and therapy of T1DM. A therapy that prevents
the destruction of the pancreatic tissue would be the ideal,
because exogenous insulin can’t equal the precision of en-
dogenous hormone secretion [6,16]. The immunotherapy
aims to prevent the onset of autoimmune phenomena in
subjects at risk (primary prevention) or counteract the
autoimmunity before T1DM occurs (secondary preven-
tion) or stop the cellular destruction and protect the
remaining functional beta cells after the clinical diagnosis
of diabetes (tertiary prevention) [5]. Once the strategies
to prevent T1DM will be identified, reliable and cost-
effective screening technologies will be also needed to
identify people at risk [14,17]. The strategy of immuno-
therapy is based on the inhibition of pathogenic cells or
in stimulating the pathways that suppress them. Non-
antigen specific immunomodulators or inhibit T-cell
proliferation or act directly on pathogenic B and T lym-
phocytes, co-stimulatory molecules, cytokines involved
in beta-cells destruction. Islet antigens specific immu-
nomodulators aim to reach and get a tolerance of long-
term through the introduction of a self-antigen capable
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flammation [5]. Insulin antibodies can be detected in
T1DM patients still before being treated with exogenous
insulin and several preproinsulin (PPI)/insulin epitopes
are recognized by T lymphocytes. In view of this ipothesis
and these findings, the mucosal administration (oral or
nasal) of insulin has been practiced clinically to try to re-
store the immunological tolerance against antigens insu-
lin. However, the insulin mucosal immunotherapy was
found to be incapable of preventing or delaying T1DM
probably because the administration of insulin would be
anticipated by the phenomenon of “antigen spreading”,
that is the progressive involvement of other PPI epitopes
or other beta cell antigens in autoimmune process. There
is no a definitive evidence that PPI/insulin is the “initiating
antigen” in human T1D and then further studies are
needed to define the role of PPI/insulin antigenicity in dif-
ferent human populations. In fact, about 20 antigens have
been identified as targets of diabetogenic T cells so far and
the list is constantly growing. Other strategies have shown
the ability to reduce the incidence of T1DM in nonobese
diabetic (NOD) mice as the intramuscular injection of a
plasmid DNA vaccine encoding proinsulin II and agonistic
insulin mimetope, but their clinical utility must be deter-
mined [6]. Several clinical trials using antigen-specific
therapies and immunomodulating agents have been
performed, but most of them turned out to be or exces-
sively toxic or unable to determine a long-term protection
of the beta cells [6], supposedly because they have not
taken into adequate consideration the fact that the re-
sidual beta cell mass and the autoimmunity differ from
patient to patient [5]. It is necessary not only to identify
suitable biomarkers of beta cell mass and the level of auto-
immunity of every diabetic patient, but also efficiently
define the formulation, dose, frequency and route of ad-
ministration of the immunomodulating agents before
designating future clinical trials. In addition, a better un-
derstanding of progression and mode of triggering the
autoimmunity in patients with T1DM and further devel-
opment of cell-based therapies and alternative sources of
beta-cells for patients without beta-cellularity should pre-
cede the planning of clinical trials. The immunotherapy
should be adapted to the condition of each patient's
disease and is currently limited by the lack of efficient
immunoreactive to beta cell antigens and appropriate bio-
markers to assess the residual beta cell mass and correlat-
ing with a successful induction of a protective immune
response following an antigen-specific therapy. The avail-
ability of such biomarkers would be particularly useful
and important before exposing patients, particularly chil-
dren and prediabetic individuals clinically healthy, at the
reagents developed to interfere with their immune system
[5]. The possible development in the future of biomarkers
capable of staging the disease more accurately and topredict the rate of progression may help to stratify patients
for future clinical trials [14]. In the context of immuno-
therapy of diabetes, TNF-alpha is a rational target not only
because is cytotoxic to pancreatic beta cells [4,7], but also
because some studies have found high levels of this cyto-
kine compared to controls in subjects in whom had been
recently diagnosed with T1DM [4]. These values remain
high even when the function of pancreatic beta cells is
completely compromised, making hypothesize that hyper-
glycemia is associated with the persistence of chronic in-
flammation [4]. Some paradoxical effects of TNF-alpha
reported in the literature and those of anti-TNF-alpha de-
scribed in several case reports may raise doubts about the
application of immunotherapy in these patients [16]. In
fact, it was described a case of T1DM began five months
after the start of therapy with etanercept in a 7 year old
girl suffering since the age of 4 years from polyarticular
JIA. The development of diabetes in this patient could be
considered independent from the drug since it is known
that JIA and T1DM can coexist. Furthermore, this child
had a family history of T1DM and positivity for anti-
GAD autoantibodies even before starting therapy with
etanercept [18]. Theoretically, biological therapy may
have triggered prematurely diabetes in this patient
predisposed, so it is important not to exclude the possi-
bility that new autoimmune processes may manifest
during therapy with etanercept in patients with JIA [18],
as well as alterations in glycemia [19,20]. In fact, a 55
year old woman suffering from the age of 30 from
T1DM and afflicted by rheumatoid arthritis 3 years after
had several episodes of severe hypoglycemia following
the administration of etanercept and adalimumab, prob-
ably due to an increased sensitivity to the action of insu-
lin due to blockade of the action of TNF-alpha in
adipose tissue level [19]. Several episodes of hypo-
glycaemia after the initiation of anti-TNF-alpha therapy
have been reported in two women with rheumatoid
arthritis, one also affected by type 2 diabetes [20] and
the other by latent autoimmune diabetes of adults
(LADA) [21], for which it was necessary to reduce, in
both of them, the doses of exogenous insulin [20,21]. In
an elderly man suffering from type 2 diabetes and psor-
iasis treated with etanercept, insulin was gradually
reduced and finally replaced with rosiglitazone and
repaglinide for frequent episodes of hypoglycaemia oc-
curred [22]. The case of a woman suffering from JIA
who developed T1DM during treatment with etanercept
has been also described. This patient also had positivity
for anti-GAD autoantibodies before starting biological
therapy, which in this case was found to be ineffective
in preventing the development and progression of
diabetes [23]. On the hypothesis that anti-TNF therapy
may preserve the function of pancreatic beta cells,
etanercept was introduced into the treatment regimen
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the diagnosis of LADA allowing to keep a low insulin dose
and good metabolic control during his eleven years of dis-
ease [24]. By the way, a small randomized, controlled,
double-blind trial lasted 24 weeks has been recently real-
ized in eighteen patients (11 males and 7 females, aged be-
tween 7.8 and 18.2 years) with T1DM recently diagnosed
(since about 4 weeks) who received placebo or etanercept.
The purpose of this study was to collect data on the cap-
acity and effectiveness of etanercept to prolong endogen-
ous insulin production and was founded on hypothesis
that the administration of etanercept could extend the
period of partial remission of diabetes (“honeymoon”). The
authors noted lower glycosylated hemoglobin and in-
creased endogenous insulin production with consequent
reduction of exogenous requests in the group of patients
treated with etanercept. They concluded that the adminis-
tration of etanercept at doses used for the treatment of
JIA is well tolerated in pediatric patients with T1DM type
1, protects the function of pancreatic beta cells by deter-
mining the reduction in insulin requirements and improv-
ing glycemic control [4]. These observations are very
interesting, but deserve further and more extensive re-
search as it is simplistic to assert that etanercept improves
the function of beta-cells by reducing the levels of TNF-
alpha, since this cytokine plays a much more complex in
the progression of diabetes [7]. Considering the disap-
pointing results of almost all clinical trials based on the
use of only one immunomodulatory agent, a future ap-
proach in hindering the progression of diabetes could be
the combined use of substances which have already been
tested for T1DM or other autoimmune diseases, and
which have a synergistic or complementary mechanisms
of action. Etanercept is an ideal candidate for a combined
therapeutic approach. Such combination therapy may in-
clude the following components: 1) an agent depleting T
effector cells, ideally given when islet specific effector re-
sponses are at their peak; 2) an anti-inflammatory agent
given for a short period at the induction of therapy; 3) an
agent that induces antigen-specific regulatory T-cells,
ideally given at the time point when the number of the T-
regs specific for beta-cells antigens is declining; 4) an
agent promoting beta-cell regeneration or the transplant-
ation of beta-cells [5]. Many therapeutic approaches for
the generation of new beta cells have been studied so far.
Induction therapy of beta cells that have any chance of
success must be accompanied by a powerful immunother-
apy that protects newly formed cells, which would other-
wise be destroyed by the autoimmune T lymphocytes. But
the autoimmunity is not the only obstacle to the clinical
application of beta cell regeneration. In fact, an efficient
gene therapy that induces beta cell neoformation in vivo
is still based primarily on viral vectors, which present
themselves a significant immunogenicity and toxicity.Moreover, the neogenesis of beta cells mature in vitro
from pluripotent stem cells is still insufficient to obtain
a clinically relevant number of cells for a therapy.
Finally, a further obstacle to the clinical application is
given by the oncogenicity of pluripotent cells and thus
preclinical studies are needed to overcome these limita-
tions. A possible successful strategy would be to counter
the autoimmunity with a strong short-term immunosup-
pression (FcR non-binding anti-CD3 mAb, anti-CD20
mAb or ATG) and prevent autoimmune reaction with
long-term or intermittent immunotherapies that target
costimulatory signals or cytokines (CTLA-4-Ig or IL-1
blocker) [6]. These combinated therapies are limited by
the fact that there are actually few preclinical studies test-
ing combinations of immunomodulatory agents and be-
cause it would be difficult to differentiate the individual
contribution of efficacy and toxicity of two or more drugs
when administered simultaneously [5]. A suggestive target
of a future immunotherapeutic approach is offered by the
trimolecular complex that is represented by HLA mole-
cules, autoantigenic peptides and the TCR of a CD4 cell.
A plausible therapeutic strategy could be offered by small
molecules that block the presentation of the autoantigen
or the recognition by the TCR of MHC-autoantigen com-
plex or monoclonal antibodies against the trimolecular
complex [5,25]. However, the effects that would result
from blocking the entire molecule MHC II are still uncer-
tain and risky [5,6]. A further opportunity of developing
safe and effective immunotherapies in the future could
result from further research whose purpose is to define
and improve the knowledge on the molecular basis
underlying the T cell response to pancreatic islet anti-
gens in T1DM [6].
Conclusions
We decided to treat our patient suffering from JIA
with an anti-TNF-alpha therapy because unresponsive
to conventional therapy with NSAIDs and MTX. More-
over, a recent randomized, double blind, placebo con-
trolled trials has shown that etanercept appears to be
well tolerated from children suffering from T1DM and
that if administered within 4 weeks after the onset of
diabetes would be able to preserve the function of pan-
creatic beta cells. This case report demonstrates that
etanercept is really effective and safe for the treatment
of JIA associated with T1DM and AHT. In fact our pa-
tient, in which diabetes was debuted long before arthritis
and so its period of partial remission (honeymoon) was
already exhausted, has not presented until now none of
the side effects associated with this therapy apart from
few episodes of hypoglycemia resolved with reduction in
insulin requirements and probably due to increased tis-
sue sensitivity induced by suppression of TNF-alpha ac-
tivity. We do not exclude an additional beneficial effect
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with much more attention and frequency due to her re-
fractory arthritis and to the administration of a drug such
as etanercept, whose adverse effects are not well known.
For these reasons, we also asked the patient to increase
the frequency of the home glucose monitoring and pay
particular attention to diet. The presumed mechanism of
action of etanercept, according to which it would improve
the function of the beta-cells by counteracting the action
of TNF may not have played a role in the case of our pa-
tient, since her diabetes was clinically began about 10
years before and serum concentrations C-peptide did not
increase upon treatment with etanercept. Further and lon-
ger studies on a larger group of patients are needed to
evaluate the ability of etanercept and other biological
drugs in preventing or delaying the development of dia-
betes and to assess its safety, efficacy and tolerability in pa-
tients with JIA and T1DM. A better knowledge of the
genetic mutations and cytokine pattern are essential to
undertake targeted and more effective therapies in differ-
ent subgroups of patients.
Consent
Written informed consent has been obtained from the
patient and her relatives for the publication of this case
report and 2 accompaying figures. A copy of the written
consent is available for review by the Editor in Chief of
this journal.
Abbreviations
TNF: Tumor necrosis factor; HLA: Human leukocyte antigen; CTLA4: Cytotoxic
T-lymphocyte-associated protein 4; PTPN22: Protein tyrosine phosphatase
non-receptor 22; HbA1c: Glycosylated hemoglobin; ICA: Islet cell
autoantibodies; GADA: Glutamic acid decarboxylase autoantibodies; IA-
2: Insulinoma associated antigen-2; Anti-TgAbs: Anti-thyroglobulin antibodies;
Anti-TPOAbs: Anti-thyroid peroxidase antibodies; BMI: Body mass index;
ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; ENA: Extractable
nuclear antigens; ANA: Anti-nuclear antibody; ATA: Anti-transglutaminase
antibodies; T-reg: Regulatory T; FcR: Fc receptor; CD3: Cluster of
differentiation 3; CD20: Cluster of differentiation 20; mAb: Monoclonal
antibody; ATG: Antithymocyte globulin; IL-1: Interleukin-1; TCR: T-cell
receptor; CD4: Cluster of differentiation 4; MHC: Major Histocompatibility
Complex.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FP and DI have made the diagnosis of type 1 diabetes mellitus, autoimmune
thyroiditis and hypothyroidism and take care of the patient. They have
participated in the conception and design of the manuscript, revisiting it.
ANO formulated the diagnosis of arthritis, take care of the patient,
participated in the conception and design of the manuscript, revisiting it.
AM take care of the patient, formulated the diagnosis of arthritis and
conceived, wrote and revisited the manuscript. AZ, AMA, CG, MFG and LP
take care of the patient and have been involved in drafting the manuscript
and revisiting it. All authors read and approved the final manuscript.
Authors’ information
Alma Nunzia Olivieri, doctor and researcher in pediatrics. Pediatric
rheumatological center.Dario Iafusco, doctor and researcher in pediatrics. Pediatric diabetological
center.
Antonio Mellos, medical doctor, intern in pediatrics. Pediatric
rheumatological center.
Zanfardino Angela, pediatrician. Pediatric diabetological center.
Angela Mauro, medical doctor, intern in pediatrics. Pediatric rheumatological
center.
Carmela Granato, medical doctor, intern in pediatrics. Pediatric
rheumatological center.
Maria Francesca Gicchino, medical student. Pediatric rheumatological center.
Francesco Prisco, professor of Pediatrics. Pediatric diabetological center.
Laura Perrone, professor of Pediatrics and director of the Department.
Received: 2 July 2013 Accepted: 6 October 2013
Published: 14 October 2013References
1. Nagy KH, Lukacs K, Sipos P, Hermann R, Madacsy L, Soltesz G: Type 1
diabetes associated with Hashimoto's thyroiditis and juvenile
rheumatoid arthritis: a case report with clinical and genetic
investigations. Pediatr Diabetes 2010, 11(8):579–582.
2. Pohjankoski H, Kautiainen H, Kotaniemi K, Korppi M, Savolainen A:
Autoimmune diseases in children with juvenile idiopathic arthritis.
Scand J Rheumatol 2010, 39(5):435–436.
3. Barker JM: Clinical review: type 1 diabetes-associated autoimmunity:
natural history, genetic associations, and screening. J Clin Endocrinol
Metab 2006, 91(4):1210–1217.
4. Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T:
Etanercept treatment in children with new-onset type 1 diabetes: pilot
randomized, placebo-controlled, double-blind study. Diabetes Care 2009,
32(7):1244–1249.
5. Schneider DA, Kretowicz AM, von Herrath MG: Emerging immune
therapies in type 1 diabetes and pancreatic islet transplantation.
Diabetes Obes Metab 2013, 15(7):581–592.
6. Chen W, Xie A, Chan L: Mechanistic basis of immunotherapies for type 1
diabetes mellitus. Transl Res 2013, 161(4):217–229.
7. Peters MJ: Etanercept treatment in children with new-onset type 1
diabetes: pilot randomized, placebo-controlled, double-blind study:
response to Mastrandrea et al. Diabetes Care 2009, 32(12):e153.
author reply e154.
8. Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, Cerutti F,
Gargantini L, Greggio N, Tonini G, Cicognani A: Italian cross-sectional
growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest
2006, 29(7):581–593.
9. Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls.
Arch Dis Child 1969, 44(235):291–303.
10. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X,
Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P:
International League of Associations for Rheumatology. International
League of Associations for Rheumatology classification of juvenile
idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004,
31(2):390–392.
11. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM,
Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto
N: 2011 American College of Rheumatology recommendations for the
treatment of juvenile idiopathic arthritis: initiation and safety monitoring
of therapeutic agents for the treatment of arthritis and systemic
features. Arthritis Care Res (Hoboken) 2011, 63(4):465–482.
12. Kemper AR, Van Mater HA, Coeytaux RR, Williams JW Jr, Sanders GD:
Systematic review of disease-modifying antirheumatic drugs for juvenile
idiopathic arthritis. BMC Pediatr 2012, 15:12–29.
13. Cronstein B: How does methotrexate suppress inflammation? Clin Exp
Rheumatol 2010, 28(5 Suppl 61):S21–S23.
14. Insel RA: Delivering on George Eisenbarth's visionary pursuit of
understanding pathogenesis and prevention of type 1 diabetes.
Diabetes Technol Ther 2013, Suppl 2:S2-4–S2-7.
15. Eisenbarth GS: Type I diabetes mellitus. a chronic autoimmune disease.
N Engl J Med 1986, 314(21):1360–1368. Review.
16. Luo X, Herold KC, Miller SD: Immunotherapy of type 1 diabetes: where
are we and where should we be going? Immunity 2010, 32(4):488–499.
Olivieri et al. Italian Journal of Pediatrics 2013, 39:64 Page 7 of 7
http://www.ijponline.net/content/39/1/6417. Spain LM, Martey L, Akolkar B, Leschek E, Appel M, Fradkin J: NIH research
to prevent type 1 diabetes: George Eisenbarth's legacy. Diabetes Technol
Ther 2013, 15 Suppl 2:S2-1–S2-3.
18. Bloom BJ: Development of diabetes mellitus during etanercept therapy
in a child with systemic-onset juvenile rheumatoid arthritis.
Arthritis Rheum 2000, 43(11):2606–2608.
19. Boulton JG, Bourne JT: Unstable diabetes in a patient receiving anti-TNF-
alpha for rheumatoid arthritis. Rheumatology (Oxford) 2007, 46(1):178–179.
20. Bonilla E, Lee YY, Phillips PE, Perl A: Hypoglycaemia after initiation of
treatment with etanercept in a patient with type 2 diabetes mellitus.
Ann Rheum Dis 2007, 66(12):1688.
21. Arif S, Cox P, Afzali B, Lombardi G, Lechler RI, Peakman M, Mirenda V: Anti-
TNF alpha therapy-killing two birds with one stone? Lancet 2010,
375(9733):2278.
22. Cheung D, Bryer-Ash M: Persistent hypoglycemia in a patient with
diabetes taking etanercept for the treatment of psoriasis. J Am Acad
Dermatol 2009, 60(6):1032–1036.
23. Tack CJ, Kleijwegt FS, Van Riel PL, Roep BO: Development of type 1
diabetes in a patient treated with anti-TNF-alpha therapy for active
rheumatoid arthritis. Diabetologia 2009, 52(7):1442–1444.
24. Montes VN, Hirsch IB: Treatment of LADA with etanercept. Diabetes Care
2012, 35(5):e36.
25. Michels AW, Nakayama M: The anti-insulin trimolecular complex in type 1
diabetes. Curr Opin Endocrinol Diabetes Obes 2010, 17(4):329–334.
doi:10.1186/1824-7288-39-64
Cite this article as: Olivieri et al.: Refractory rheumatoid factor positive
polyarthritis in a female adolescent already suffering from type 1
diabetes mellitus and Hashimoto’s thyroiditis successfully treated with
etanercept. Italian Journal of Pediatrics 2013 39:64.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
